+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
S

Actively Recruiting

Researchers are evaluating the performance and safety of the SUREcore biopsy needle and the coreCARE specimen retrieval device compared to a standard biopsy needle and tissue container in men undergoing prostate biopsy. The study aims to assess whether these new devices improve the quality and completeness of prostate tissue samples, which are often fragmented with current biopsy tools. This post-market study is sponsored by Uro-1 Medical and involves men diagnosed with prostate disease or prostate cancer. Participants will undergo prostate tissue biopsy following a 12-core systematic template. Six samples will be collected using the standard biopsy needle and six with the SUREcore needle. The tissue samples will then be randomly retrieved either by the swiping method or using the coreCARE device. The study compares the amount and quality of tissue collected with each method, and users will rate the ease of use of the biopsy tools during the procedure. During and up to five days after the biopsy procedure, researchers will monitor for any adverse events. Pathologists will evaluate the quality of the tissue cores obtained, and users will provide feedback on the biopsy devices. Primary outcomes measured include procedure success, core tissue length, tissue weight, and tissue sample preparation, all assessed on the day of the procedure. Participants will also be asked to verbally assess their condition five days following the biopsy.

Age: 18Years - 90YearsMALEPhase Not Applicable
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination drug called VNX001 compared to placebo and its individual components, lidocaine hydrochloride and heparin sodium, in people with interstitial cystitisbladder pain syndrome ICBPS who are experiencing an episode of moderate to severe bladder pain. This Phase 2, multi-center, randomized, double-blind, placebo-controlled study aims to better understand how these treatments reduce bladder pain during acute episodes. Participants will be randomly assigned to receive a single dose of VNX001, placebo alkalinized phosphate buffer, alkalinized lidocaine, or alkalinized heparin. The treatments are administered through intravesical instillation directly into the bladder. After 24 to 48 hours, all participants have the option to receive a single open-label dose of VNX001. The randomization ratio is 3131 for VNX001, placebo, lidocaine, and heparin respectively. Throughout the study, participants will have their bladder pain intensity measured at various time points up to 24 hours after dosing using pain scales and questionnaires. Researchers will also monitor the use of the optional open-label VNX001 dose at 48 hours and track any adverse events for 72 hours. The total involvement includes screening, a single treatment visit, and follow-up assessments to evaluate pain relief and safety.

Age: 18Years +All GendersPhase 2
14 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and dosing frequency of VNX001 in people with Interstitial CystitisBladder Pain Syndrome ICBPS, a condition causing moderate to severe bladder pain. This Phase 2b, open-label study focuses on treating acute episodes of bladder pain and aims to count the number of doses used and measure pain levels before and after treatment. The research also monitors how well participants tolerate VNX001 and any side effects. Participants will receive up to six doses of VNX001 administered directly into the bladder through a catheter over a 14-day period. Each dose contains 15 mL of buffered lidocaine HCl and sodium heparin. The study includes up to seven clinic visits, which cover screening and dosing appointments, or at least one combined screening and dosing visit plus five telephone calls. The dosing is given as needed based on pain episodes. During the study, participants will record their bladder pain, urinary urgency, side effects, and any medications taken daily via a diary or telephone calls. Researchers will assess pain changes at multiple time points after dosing and track overall symptom improvement. Safety is monitored through adverse event reporting up to 17 days. The study lasts 14 days, during which participants will have frequent contact with the clinic for evaluations and support.

Age: 18Years +All GendersPhase 2
5 locations